Researchers at the University of California, Davis have developed smart, supramolecular, materials that can assemble into nanoparticles. These particles can then be used to target tumor cells.

Electrophysiological devices are critical for mapping eloquent and diseased brain regions and for therapeutic neuromodulation in clinical settings and are extensively utilized for research in brain-machine interfaces. However, the existing devices are often limited in either spatial resolution or cortical coverage, even including those with thousands of channels used in animal experiments.

UC Berkeley researchers have discovered novel, specific Fem1b inhibitors. Fem1b is essential in lymphoma and lung cancer cells.  Fem1b inhibition could be beneficial in cancer, metabolic disease, obesity, diabetes and other diseases. 

Researchers at the University of California, Davis have developed a surgical device to facilitate vascular anastomosis procedures with enhanced ease and speed.

Researchers at the University of California, Davis have developed a potential drug target for cancer and inflammation by studying the binding of integrins to P-selectin.

Researchers at the University of California, Davis have developed a potential therapeutic treatment for sepsis by modulating the interaction between integrins and Myeloid Differentiation factor 2 (MD-2).

Researchers at the University of California, Davis have developed dominant-negative FGF2 antagonists that suppress angiogenesis and tumor growth.

Researchers at the University of California, Davis have developed a large area sensor array for ultrasound imaging systems that utilizes high-bandwidth piezoelectric sensors and modular design elements.